Results 191 to 200 of about 406,228 (357)

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

Med Research, EarlyView.
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdu, Zhengrui Li, Jian Zhang, Peng Luo   +8 more
wiley   +1 more source

RRP12 Variants Are Associated With Autosomal Recessive Brain Calcifications

Movement Disorders, EarlyView.
Abstract Background Primary brain calcifications are observed in several inherited diseases due to different pathogenic mechanisms, including the disruption of the neurovascular unit, mitochondrial dysfunction, and impaired nucleic acid metabolism.
Edoardo Monfrini, Paola Rinchetti, Mathieu Anheim, Anna Klingseisen, Ouhaid Lagha‐Boukbiza, Zhidong Cen, Dehao Yang, Xinhui Chen, Reza Maroofian, Henry Houlden, Gioia Cappelletti, Anne‐Claire Richard, Olivier Quenez, Camilo Toro, Steven J. Frucht, Francesco Lotti, Wei Luo, David Hunt, Gael Nicolas, Giulietta M. Riboldi   +19 more
wiley   +1 more source

The on-going controversy of target thyroid stimulating hormone: Time for pragmatism. [PDF]

Obstet Med
Wiles K, Nana M, Nelson-Piercy C.
europepmc   +1 more source

Macro-TSH Can Be a Rare Cause of Elevated Serum Thyroid Stimulating Hormone Concentration: A Case Report

, 2014
Hande Peynirci, Canan Ersoy, Ahmet Ziya Şahin, Şazi İmamoğlu   +3 more
openalex   +1 more source

Altered Dopamine Metabolism and Response to Treatment with Levodopa/Carbidopa in MCT8 Deficiency

Movement Disorders, EarlyView.
Abstract Background Allan‐Herndon‐Dudley syndrome (AHDS)/monocarboxylate transporter 8 (MCT8) deficiency is a rare X‐linked encephalopathy caused by SLC16A2 variants, impairing thyroid hormone (TH) transport into the brain. This leads to early central nervous system (CNS) TH deficiency, affecting brain maturation.
Fabio Bruschi, Ylenia Vaia, Clara E. Antonello, Marco Spada, Francesco Porta, Cristina Marinaccio, Claudia Carducci, Thomas Opladen, Jacopo Sartorelli, Federica Maria Zibordi, Daniele Ghezzi, Francesco Nicita, Davide Tonduti   +12 more
wiley   +1 more source

Thyroid-Stimulating Hormone/Growth Hormone Cosecreting Pituitary Adenoma With Normal Thyroid-Stimulating Hormone Level. [PDF]

JCEM Case Rep
Erenler F, Katcher B, Phan V, Arkun K, Safain MG.   +4 more
europepmc   +1 more source

Persistent hypothyroid symptoms in a patient with a normal thyroid stimulating hormone level

Current Opinion in Endocrinology, Diabetes & Obesity, 2017
J. Jonklaas
semanticscholar   +1 more source

Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications

Medicinal Research Reviews, EarlyView.
ABSTRACT Targeted radioligand therapy has emerged as a promising treatment option for eradicating advanced cancer forms. α‐Emitters are considered particularly promising as they can obliterate (micro)‐metastases. The α‐emitter astatine‐211 (211At) has experienced increased interest due to its favorable decay properties.
Marius Müller, Nadia Bom Pedersen, Vladimir Shalgunov, Andreas Ingemann Jensen, Umberto Maria Battisti, Matthias Manfred Herth   +5 more
wiley   +1 more source

Effects of thyroid-stimulating hormone and sensitivity to thyroid hormones on the risk of hyperuricemia in euthyroid adults. [PDF]

Arch Endocrinol Metab
Ding H, Liang Y, Wang Y, Zhang K, Zhu M, Jing Y, Xue Y, Chen X, Zhou H, Dong C.   +9 more
europepmc   +1 more source

The disulphide bond structure of thyroid-stimulating hormone β-subunit [PDF]

, 1996
W. Douglas Fairlie, Peter G. Stanton, Milton T. W. Hearn   +2 more
openalex   +1 more source